Dr. Kinyas Hair Clinic · Science and Research Centre
Finasteride and Hair Transplantation: An Informed Choice for Existing Hair
Transplant planning considers both the implanted hair and existing hair that may continue to thin over the years. Finasteride may form part of this long-term plan in suitable men. Expected benefits, adverse effects and your willingness to take it should be discussed with equal clarity.
It targets AGA, rather than creating new follicles
Finasteride inhibits type II 5-alpha-reductase, involved in converting testosterone to DHT. It targets miniaturisation in genetically susceptible follicles; it does not remove genetic susceptibility. Follicle condition and the pattern of loss inform individual expectations. Not all hair loss should be assumed to be AGA. [1]
Rather than asking only for a predicted hair count, ask which hairs treatment aims to preserve, what baseline records are needed and how response will be assessed. Marked inflammation, sudden shedding or an unusual distribution require differential diagnosis before treatment selection.
How should effectiveness evidence be interpreted?
A 2010 systematic review assessed 12 eligible studies involving 3,927 men. Patient ratings and hair counts favoured finasteride. However, this older evidence does not include all subsequently identified safety information. Effectiveness and current risks should be considered using complementary sources. [2]
A higher proportion of participants reporting improved appearance does not mean one person gains the same percentage of additional hair. Group averages do not guarantee an individual response. The S3 guideline also emphasises individualised selection and treatment continuity. [1], [2]
What did the transplant-related study measure?
A double-blind, placebo-controlled study of 79 men assessed finasteride in relation to non-transplanted hair around the transplant and overall appearance. Hair counts and photographic assessments were better in the treatment group. [3]
This does not establish a guaranteed graft-survival percentage or a requirement for every transplant patient to take medication. The study’s preoperative and postoperative schedule is not reproduced as a personal prescription. Preserving surrounding existing hair and improving surgical graft survival are different goals.
When and how should response be assessed?
Finasteride is not assessed over days. Evaluation takes months, using baseline photographs, the distribution of loss, regular-use records and tolerability. Maintaining benefits may require continued treatment; stopping may lead to loss of effect over time. This does not imply sudden or equally severe shedding in every person. [1], [4]
Do not increase the dose for an apparently inadequate response before diagnosis and use have been reviewed. Discuss the difference between tablets studied for hair loss and higher-dose tablets for other indications using product information and your personal plan. A higher dose does not automatically produce a better hair result. [1], [4]
How should sexual symptoms be addressed?
Reduced libido, erectile difficulties and ejaculation problems have been reported. Controlled-trial rates and spontaneous post-marketing reports use different methods; they cannot provide one certain personal risk percentage. Persistent symptoms should neither be dismissed nor presented as inevitable for everyone. [4], [5]
The MHRA update of 11 May 2026 stresses that sexual dysfunction may persist after stopping. Discuss existing symptoms before treatment and report changes during follow-up. Contact your prescriber for new symptoms; seeking support is part of reassessment. [5]
Current warnings about mood changes
In its 2025 review, EMA confirmed suicidal ideation as an adverse effect of oral finasteride tablets, with unknown frequency. People developing mood changes while taking 1 mg for hair loss are advised to stop and seek medical advice promptly. Unknown frequency means available data cannot quantify the risk. [6]
The 2026 MHRA update also stresses reviewing depression history and psychiatric or sexual symptoms regularly. These warnings inform decisions, rather than predicting severe problems for everyone. Suicidal thoughts or threats to immediate safety require urgent medical assessment, not a routine appointment. [5]
Does topical finasteride mean zero risk?
In a 24-week phase III trial, 458 men were randomised and 323 completed it. The studied spray improved target-area hair counts versus placebo, with lower systemic exposure than oral treatment. This does not mean no absorption or identical safety across formulations. [7]
The trial had commercial support and author affiliations. A published correction also fixes a discontinuation statement in which the oral group was mislabelled. Evidence for that particular spray should not automatically be applied to a pharmacy-compounded formulation of another concentration. [7], [8]
Why discuss pregnancy, fertility and PSA?
Finasteride must not be used during pregnancy. Observe product warnings about pregnant people or those who may become pregnant handling crushed or broken tablets. Studies in adult men do not directly apply to women or children. [4]
Tell your doctor about fertility concerns or plans for pregnancy. Anyone interpreting a PSA test should know you take finasteride, because it can affect the result. An internet article cannot establish the cause of an individual sperm, PSA or sexual-function concern. These require clinical and, when appropriate, specialist assessment. [1], [4]
How does declining medication affect transplant planning?
Do not conceal a treatment you cannot or do not wish to use. Discuss ongoing loss, donor reserves and future appearance together. Declining medication does not automatically rule out surgery, but may change the assumptions behind long-term planning. [1] (clinical decision framework)
At your consultation with Dr. Kinyas, clarify the expected contribution of medication, alternatives, monitoring and how to report adverse effects. This article does not claim that everyone receives the same medication or that finasteride is compulsory for transplantation.
References and access limitations
This article is based on a targeted review of sources; it is not an original systematic review.
- Kanti V et al. Evidence-based (S3) guideline for AGA – short version. JEADV. 2018;32:11–22. DOI: 10.1111/jdv.14624.
Guideline. Literature search to 2015; it does not replace subsequently updated safety information.
- Mella JM et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141–1150. DOI: 10.1001/archdermatol.2010.256.
Systematic review; accessible abstract. Twelve studies involving 3,927 men were checked against bibliographic information and the abstract; the full review and every primary study were not considered read. Earlier draft risk figures were not reused without renewed verification.
- Leavitt M et al. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005;31:1268–1276. DOI: 10.1111/j.1524-4725.2005.31202.
Randomised trial; abstract. Seventy-nine men, groups of 40 and 39; non-transplanted hair and appearance. Full-text details were not reviewed; two authors were affiliated with Merck. The count was not presented as a graft-survival percentage.
- PROPECIA prescribing information. United States, revised August 2022.
Product information: relevant indication, warning and patient-information sections reviewed, supplemented by current EMA/MHRA warnings. Not a Turkish product authorisation or SmPC. High-dose prostate studies were not directly translated into hair-loss treatment recommendations.
- MHRA. Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. 11 May 2026.
Regulatory safety review. Relevant official sections reviewed. Spontaneous reports were not converted into incidence; UK guidance does not replace Turkish authorisation.
- EMA. Finasteride- and dutasteride-containing medicinal products, 2025 review.
Regulatory safety review. Based on the official regulatory assessment. Frequency is unknown. A favourable benefit–risk balance in approved indications does not mean absence of risk for everyone.
- Piraccini BM et al. Efficacy and safety of topical finasteride spray solution for male AGA: a phase III, randomized, controlled clinical trial. JEADV. 2022;36:286–294. DOI: 10.1111/jdv.17738.
Randomised trial; abstract and indexed information: 458 randomised, 323 completers, 446 in safety assessment. Assessment is limited to the abstract and indexed information. Indexed disclosures include Almirall/Polichem support and Almirall author affiliations. Insufficient to determine long-term risks.
- Corrigendum. JEADV. 2023;37:452. DOI: 10.1111/jdv.18750.
Published correction: the 7.1% discontinuation rate for treatment-related events belongs to the oral finasteride group, incorrectly described as topical in the original sentence. It is not a general rate of sexual adverse effects.